{
    "data": [
        {
            "id": "2785845",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-30T15:05:04-05:00",
                "isLockedPro": false,
                "commentCount": 102,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Morgan Stanley Provides Some Sage Words On Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147843",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2785845-morgan-stanley-provides-some-sage-words-on-gilead-sciences"
            }
        },
        {
            "id": "2788445",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-30T14:10:51-05:00",
                "isLockedPro": false,
                "commentCount": 32,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Long-Term Prognosis Is Promising",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2788445-gilead-long-term-prognosis-is-promising"
            }
        },
        {
            "id": "2788235",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-30T12:36:58-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gauging The Impact Of Express Scripts/AbbVie Agreement On Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147932",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2788235-gauging-the-impact-of-express-scripts-abbvie-agreement-on-gilead"
            }
        },
        {
            "id": "2787305",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-30T07:08:21-05:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Extremely Attractive At These Levels",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "68625",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147901",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2787305-gilead-sciences-extremely-attractive-at-these-levels"
            }
        },
        {
            "id": "2785795",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-29T14:52:30-05:00",
                "isLockedPro": false,
                "commentCount": 124,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: After The Bloodbath The Stock Is A Strong Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147842",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2785795-gilead-sciences-after-the-bloodbath-the-stock-is-a-strong-buy"
            }
        },
        {
            "id": "2777795",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-24T22:42:40-05:00",
                "isLockedPro": false,
                "commentCount": 189,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Reason To Be Bearish On Gilead - Everyone Seems Bullish",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2777795-a-reason-to-be-bearish-on-gilead-everyone-seems-bullish"
            }
        },
        {
            "id": "2775525",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-24T07:59:42-05:00",
                "isLockedPro": false,
                "commentCount": 142,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Feels The Heat Of Competition",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775525-gilead-feels-the-heat-of-competition"
            }
        },
        {
            "id": "2775385",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-24T07:18:23-05:00",
                "isLockedPro": false,
                "commentCount": 95,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "4 Reasons I'm Adding Gilead To My Healthcare Holdings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24663",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147528",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775385-4-reasons-im-adding-gilead-to-my-healthcare-holdings"
            }
        },
        {
            "id": "2775465",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-23T07:35:34-05:00",
                "isLockedPro": false,
                "commentCount": 102,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Buy On The Drop?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74295",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147533",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775465-gilead-sciences-buy-on-the-drop"
            }
        },
        {
            "id": "2775445",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-23T07:27:39-05:00",
                "isLockedPro": false,
                "commentCount": 270,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Who Is The Devil? Will Gilead Fall Or Soar In 2015?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147531",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775445-who-is-the-devil-will-gilead-fall-or-soar-in-2015"
            }
        },
        {
            "id": "2775325",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-23T07:02:29-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Express Scripts Knocks Gilead's Hep C Drug In Favor Of AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "47691",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775325-express-scripts-knocks-gileads-hep-c-drug-in-favor-of-abbvie"
            }
        },
        {
            "id": "2775225",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-23T05:50:20-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Cramer's Mad Money - Is Competition Killing Gilead? (12/22/14)",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20187",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2775225-cramers-mad-money-is-competition-killing-gilead-12-22-14"
            }
        },
        {
            "id": "2774085",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-22T17:15:18-05:00",
                "isLockedPro": false,
                "commentCount": 345,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Commentary On Gilead Sciences' Recent Plunge",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147493",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2774085-commentary-on-gilead-sciences-recent-plunge"
            }
        },
        {
            "id": "2773785",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-22T15:37:49-05:00",
                "isLockedPro": false,
                "commentCount": 84,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why I Am Not Selling Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147483",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2773785-why-i-am-not-selling-gilead"
            }
        },
        {
            "id": "2773315",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-22T14:09:23-05:00",
                "isLockedPro": false,
                "commentCount": 218,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "AbbVie Versus Gilead In Hepatitis C, With Comments On Biotech",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147467",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2773315-abbvie-versus-gilead-in-hepatitis-c-with-comments-on-biotech"
            }
        },
        {
            "id": "2769075",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-20T12:51:16-05:00",
                "isLockedPro": false,
                "commentCount": 439,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: What's Ahead In 2015 For This Biotech Juggernaut",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147321",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2769075-gilead-whats-ahead-in-2015-for-this-biotech-juggernaut"
            }
        },
        {
            "id": "2767355",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-19T19:55:07-05:00",
                "isLockedPro": false,
                "commentCount": 126,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "While Gilead's Profits Soar, Uncertainty Reigns Supreme At AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2767355-while-gileads-profits-soar-uncertainty-reigns-supreme-at-abbvie"
            }
        },
        {
            "id": "2768385",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-19T08:28:43-05:00",
                "isLockedPro": false,
                "commentCount": 9,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "The 2015 Calendar Of NASH Trial Catalysts IV: GENFIT And Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "75375",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2768385-the-2015-calendar-of-nash-trial-catalysts-iv-genfit-and-gilead"
            }
        },
        {
            "id": "2768175",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-19T05:45:43-05:00",
                "isLockedPro": false,
                "commentCount": 87,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: News On Gilead From The California Technology Assessment Forum",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147289",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2768175-update-news-on-gilead-from-the-california-technology-assessment-forum"
            }
        },
        {
            "id": "2765265",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-18T07:36:12-05:00",
                "isLockedPro": false,
                "commentCount": 77,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Ho Ho Harvoni: Gilead Sciences Is A Gift That Should Be Under Every Investor's Tree.",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "64493",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147186",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2765265-ho-ho-harvoni-gilead-sciences-is-a-gift-that-should-be-under-every-investors-tree"
            }
        },
        {
            "id": "2758805",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-17T07:44:59-05:00",
                "isLockedPro": false,
                "commentCount": 89,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Stands Alone",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146997",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2758805-gilead-sciences-stands-alone"
            }
        },
        {
            "id": "2758795",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-17T07:37:47-05:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Examining Gilead Sciences' Future Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146996",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2758795-examining-gilead-sciences-future-pipeline"
            }
        },
        {
            "id": "2759515",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-16T11:52:17-05:00",
                "isLockedPro": false,
                "commentCount": 46,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Assessing Gilead's Reality-Perception Gap",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "78655",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "147021",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2759515-assessing-gileads-reality-perception-gap"
            }
        },
        {
            "id": "2759065",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-16T10:04:19-05:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "How To Beat The Market - My Best Large-Cap Stock Portfolio: Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2759065-how-to-beat-the-market-my-best-large-cap-stock-portfolio-gilead-sciences"
            }
        },
        {
            "id": "2757045",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-15T15:46:04-05:00",
                "isLockedPro": false,
                "commentCount": 89,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "There Is Still Time To Join The Gilead Bandwagon",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "53222",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146946",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2757045-there-is-still-time-to-join-the-gilead-bandwagon"
            }
        },
        {
            "id": "2752415",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-12T15:27:03-05:00",
                "isLockedPro": false,
                "commentCount": 128,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences' Stock Forecast: Algorithmic And Fundamental Analysis",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50792",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2752415-gilead-sciences-stock-forecast-algorithmic-and-fundamental-analysis"
            }
        },
        {
            "id": "2742645",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-09T12:45:01-05:00",
                "isLockedPro": false,
                "commentCount": 43,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: First Oncology Drug Strengthens War Chest",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146560",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2742645-gilead-sciences-first-oncology-drug-strengthens-war-chest"
            }
        },
        {
            "id": "2738755",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-08T09:23:11-05:00",
                "isLockedPro": false,
                "commentCount": 114,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Comprehensive Comparison Of Gilead's Harvoni And AbbVie's Triple HCV Regimen: What The HCV Marketplace May Look Like In 2015 And Beyond",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146438",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2738755-a-comprehensive-comparison-of-gileads-harvoni-and-abbvies-triple-hcv-regimen-what-the-hcv-marketplace-may-look-like-in-2015-and-beyond"
            }
        },
        {
            "id": "2731605",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-05T14:52:11-05:00",
                "isLockedPro": false,
                "commentCount": 96,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead Is A Better Buy Than AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146248",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2731605-why-gilead-is-a-better-buy-than-abbvie"
            }
        },
        {
            "id": "2731765",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-04T15:14:13-05:00",
                "isLockedPro": false,
                "commentCount": 24,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: An Alpha Stock Through The Good And Bad Times",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65113",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146252",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2731765-gilead-sciences-an-alpha-stock-through-the-good-and-bad-times"
            }
        },
        {
            "id": "2725565",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-02T16:32:03-05:00",
                "isLockedPro": false,
                "commentCount": 45,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "An Update For Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2725565-an-update-for-gilead-sciences"
            }
        },
        {
            "id": "2724585",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-02T11:29:22-05:00",
                "isLockedPro": false,
                "commentCount": 116,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Set To Trounce AbbVie's HCV Combo",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "77675",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146075",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2724585-gilead-set-to-trounce-abbvies-hcv-combo"
            }
        },
        {
            "id": "2724005",
            "type": "article",
            "attributes": {
                "publishOn": "2014-12-02T08:05:27-05:00",
                "isLockedPro": false,
                "commentCount": 141,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sovaldi Versus Abbvie Combination: Analysis Of Abbvie Combination Impact On Sovaldi Market Share",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "57391",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "146059",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2724005-sovaldi-versus-abbvie-combination-analysis-of-abbvie-combination-impact-on-sovaldi-market-share"
            }
        },
        {
            "id": "2717085",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-29T08:29:56-05:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences - Investigating Earnings Predictability",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2717085-gilead-sciences-investigating-earnings-predictability"
            }
        },
        {
            "id": "2717685",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-28T13:17:00-05:00",
                "isLockedPro": false,
                "commentCount": 23,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Is Gilead Taking The Lead? - A Bullish Fundamental & Algorithmic Perspective",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "50792",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145889",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2717685-gilead-sciences-is-gilead-taking-the-lead-a-bullish-fundamental-and-algorithmic-perspective"
            }
        },
        {
            "id": "2706985",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-25T10:43:03-05:00",
                "isLockedPro": false,
                "commentCount": 148,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Despite Recent Hiccup, Gilead Is Still A Blue Chip Gem",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145608",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2706985-despite-recent-hiccup-gilead-is-still-a-blue-chip-gem"
            }
        },
        {
            "id": "2706235",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-25T07:10:17-05:00",
                "isLockedPro": false,
                "commentCount": 236,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Be Careful With Gilead - It May Be Time To Take Profits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "32751",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2706235-be-careful-with-gilead-it-may-be-time-to-take-profits"
            }
        },
        {
            "id": "2707415",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-24T13:37:27-05:00",
                "isLockedPro": false,
                "commentCount": 201,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Investors Should Be Concerned About Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "20411",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2707415-investors-should-be-concerned-about-gilead"
            }
        },
        {
            "id": "2696395",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-19T16:33:16-05:00",
                "isLockedPro": false,
                "commentCount": 94,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why We're Huge Fans Of Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24491",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2696395-why-were-huge-fans-of-gilead"
            }
        },
        {
            "id": "2695355",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-19T11:35:18-05:00",
                "isLockedPro": false,
                "commentCount": 48,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Pipeline Now Includes Potential Renal Blockbuster",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "71565",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145298",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2695355-gilead-pipeline-now-includes-potential-renal-blockbuster"
            }
        },
        {
            "id": "2691975",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-19T11:17:45-05:00",
                "isLockedPro": false,
                "commentCount": 10,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Gilead's Harvoni Receives Marketing Authorization In Europe",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2691975-update-gileads-harvoni-receives-marketing-authorization-in-europe"
            }
        },
        {
            "id": "2691105",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-19T07:45:36-05:00",
                "isLockedPro": false,
                "commentCount": 42,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Rising Net Income, Zero Debt And Strong R&D Pipeline",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24492",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145179",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2691105-gilead-rising-net-income-zero-debt-and-strong-r-and-d-pipeline"
            }
        },
        {
            "id": "2693025",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-18T16:07:54-05:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Value Without Its Hep C Franchise",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145237",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2693025-gileads-value-without-its-hep-c-franchise"
            }
        },
        {
            "id": "2687735",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-18T08:52:03-05:00",
                "isLockedPro": false,
                "commentCount": 58,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Buy Gilead Sciences Now At A Historic Low Valuation",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "66233",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145085",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2687735-buy-gilead-sciences-now-at-a-historic-low-valuation"
            }
        },
        {
            "id": "2687615",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-18T08:22:23-05:00",
                "isLockedPro": false,
                "commentCount": 194,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Dispelling Some Of The Myths Surrounding Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145083",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2687615-dispelling-some-of-the-myths-surrounding-gilead-sciences"
            }
        },
        {
            "id": "2688445",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-17T12:35:37-05:00",
                "isLockedPro": false,
                "commentCount": 65,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Has Been Rocked After Earnings, But I'm Looking To Buy!",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "145103",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2688445-gilead-has-been-rocked-after-earnings-but-im-looking-to-buy"
            }
        },
        {
            "id": "2674915",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-12T15:25:33-05:00",
                "isLockedPro": false,
                "commentCount": 325,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences Gets Ambushed By The Patent Troll, AbbVie",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "61291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144814",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/2674915-gilead-sciences-gets-ambushed-by-the-patent-troll-abbvie"
            }
        },
        {
            "id": "2674825",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-12T15:13:47-05:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Sub-Optimal 39% Hep C Cure Rate Keeps Merck In Gilead's Rear View",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144813",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2674825-sub-optimal-39-percent-hep-c-cure-rate-keeps-merck-in-gileads-rear-view"
            }
        },
        {
            "id": "2669885",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-12T11:17:40-05:00",
                "isLockedPro": false,
                "commentCount": 13,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: These 2 Combinations Will Further Strengthen Gilead's HCV Portfolio",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144700",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2669885-update-these-2-combinations-will-further-strengthen-gileads-hcv-portfolio"
            }
        },
        {
            "id": "2665415",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-11T14:10:56-05:00",
                "isLockedPro": false,
                "commentCount": 136,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Another Competitor Bites The Dust",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144633",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2665415-gilead-another-competitor-bites-the-dust"
            }
        },
        {
            "id": "2669855",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-11T11:13:12-05:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144698",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2669855-why-is-gilead-always-holding-the-ace-a-prediction-of-the-future-hcv-market-and-what-analysts-arent-talking-about"
            }
        },
        {
            "id": "2664645",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-10T11:10:58-05:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Gilead Sciences Stock Is Still A Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "22018",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144620",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2664645-why-gilead-sciences-stock-is-still-a-buy"
            }
        },
        {
            "id": "2636805",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-05T12:41:36-05:00",
                "isLockedPro": false,
                "commentCount": 75,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences - What Convinced Me To Become Bullish",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72015",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144282",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2636805-gilead-sciences-what-convinced-me-to-become-bullish"
            }
        },
        {
            "id": "2636495",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-05T11:51:35-05:00",
                "isLockedPro": false,
                "commentCount": 115,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Stay The Course",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144275",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2636495-gilead-stay-the-course"
            }
        },
        {
            "id": "2630485",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-04T08:38:26-05:00",
                "isLockedPro": false,
                "commentCount": 158,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Is AbbVie's Bullishness On Its Hepatitis C Drugs Valid?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144169",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2630485-is-abbvies-bullishness-on-its-hepatitis-c-drugs-valid"
            }
        },
        {
            "id": "2631435",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-03T12:18:34-05:00",
                "isLockedPro": false,
                "commentCount": 78,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Slaying The Last Dragons Of Doubt?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65263",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144191",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2631435-gilead-slaying-the-last-dragons-of-doubt"
            }
        },
        {
            "id": "2630525",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-03T08:49:34-05:00",
                "isLockedPro": false,
                "commentCount": 17,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's EPS Miss Is Investors' Gain: Gilead's A Buy On Harvoni Success",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "21305",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144172",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2630525-gileads-eps-miss-is-investors-gain-gileads-a-buy-on-harvoni-success"
            }
        },
        {
            "id": "2630495",
            "type": "article",
            "attributes": {
                "publishOn": "2014-11-03T08:41:44-05:00",
                "isLockedPro": false,
                "commentCount": 35,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Why Did Gilead Drop Friday? Is It Justified Or Just An Overreaction?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144170",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2630495-why-did-gilead-drop-friday-is-it-justified-or-just-an-overreaction"
            }
        },
        {
            "id": "2617765",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-31T11:43:26-04:00",
                "isLockedPro": false,
                "commentCount": 90,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Still 40% Upside Ahead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144030",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2617765-gilead-still-40-percent-upside-ahead"
            }
        },
        {
            "id": "2616255",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-31T08:14:52-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Did Gilead Sciences Really Disappoint With Its Earnings Announcement?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2616255-did-gilead-sciences-really-disappoint-with-its-earnings-announcement"
            }
        },
        {
            "id": "2610205",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-30T10:13:26-04:00",
                "isLockedPro": false,
                "commentCount": 16,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Gilead Q3 Earnings - Sovaldi Sales Are Down",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "65323",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2610205-update-gilead-q3-earnings-sovaldi-sales-are-down"
            }
        },
        {
            "id": "2610185",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-30T10:11:00-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: Gilead's Impressive Earnings Confirm Our Bull Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2610185-update-gileads-impressive-earnings-confirm-our-bull-case"
            }
        },
        {
            "id": "2610015",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-30T10:04:55-04:00",
                "isLockedPro": false,
                "commentCount": 4,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Another Solid Quarter, Long Term Appeal Remains",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25120",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2610015-gilead-sciences-another-solid-quarter-long-term-appeal-remains"
            }
        },
        {
            "id": "2616545",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-30T08:56:14-04:00",
                "isLockedPro": false,
                "commentCount": 8,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Were Gilead's Earnings Really A Disappointment?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2616545-were-gileads-earnings-really-a-disappointment"
            }
        },
        {
            "id": "2616245",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-30T08:08:49-04:00",
                "isLockedPro": false,
                "commentCount": 15,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Even More Attractive After Third Quarter Results",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "144020",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2616245-gilead-sciences-even-more-attractive-after-third-quarter-results"
            }
        },
        {
            "id": "2609855",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-29T09:34:57-04:00",
                "isLockedPro": false,
                "commentCount": 54,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Beats And (Sort Of) Raises, Stock Drops: What Gives?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143931",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2609855-gilead-beats-and-sort-of-raises-stock-drops-what-gives"
            }
        },
        {
            "id": "2605805",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-28T14:45:37-04:00",
                "isLockedPro": false,
                "commentCount": 117,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Bet The Farm On Gilead",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "31441",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2605805-bet-the-farm-on-gilead"
            }
        },
        {
            "id": "2605655",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-28T14:10:29-04:00",
                "isLockedPro": false,
                "commentCount": 21,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Whisper Number Impact: What To Expect From Gilead's Earnings",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "24051",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2605655-whisper-number-impact-what-to-expect-from-gileads-earnings"
            }
        },
        {
            "id": "2600925",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-27T13:51:05-04:00",
                "isLockedPro": false,
                "commentCount": 44,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Will Warehousing Dampen Q3 Revenues?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2600925-gilead-sciences-will-warehousing-dampen-q3-revenues"
            }
        },
        {
            "id": "2580105",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-21T15:23:48-04:00",
                "isLockedPro": false,
                "commentCount": 69,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Pricing, Politics And Profits",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143479",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2580105-gilead-sciences-pricing-politics-and-profits"
            }
        },
        {
            "id": "2578465",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-21T09:07:54-04:00",
                "isLockedPro": false,
                "commentCount": 55,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Clear The Dockets And Settle With Merck Already",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "61291",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143437",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": [
                        {
                            "id": "1302",
                            "type": "tag"
                        }
                    ]
                }
            },
            "links": {
                "self": "/article/2578465-gilead-sciences-clear-the-dockets-and-settle-with-merck-already"
            }
        },
        {
            "id": "2574465",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-20T08:27:25-04:00",
                "isLockedPro": false,
                "commentCount": 36,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead: Stage Set For Rally",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "23762",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143338",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2574465-gilead-stage-set-for-rally"
            }
        },
        {
            "id": "2570765",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-17T13:54:13-04:00",
                "isLockedPro": false,
                "commentCount": 19,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Harvoni Vs. Olysio Price War Will Be Nonexistent: Consider Buying Gilead Now",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "73255",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143255",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2570765-a-harvoni-vs-olysio-price-war-will-be-nonexistent-consider-buying-gilead-now"
            }
        },
        {
            "id": "2563755",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-15T11:20:36-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "A Review Of Gilead's Harvoni, And Competitive Considerations",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "43041",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143103",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2563755-a-review-of-gileads-harvoni-and-competitive-considerations"
            }
        },
        {
            "id": "2563485",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-15T09:24:55-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead's Harvoni Will Dominate J&J's Olysio In HCV: Is Olysio Even Relevant Anymore?",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "72465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "143093",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2563485-gileads-harvoni-will-dominate-j-and-js-olysio-in-hcv-is-olysio-even-relevant-anymore"
            }
        },
        {
            "id": "2563155",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-15T07:48:47-04:00",
                "isLockedPro": false,
                "commentCount": 22,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Has Taken A Pounding But Is Almost At A Level That I Want To Buy",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44001",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2563155-gilead-has-taken-a-pounding-but-is-almost-at-a-level-that-i-want-to-buy"
            }
        },
        {
            "id": "2561745",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-14T16:32:22-04:00",
                "isLockedPro": false,
                "commentCount": 29,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Gilead Sciences: Ignore Recent Insider Selling",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "74465",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2561745-gilead-sciences-ignore-recent-insider-selling"
            }
        },
        {
            "id": "2560215",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-14T10:06:37-04:00",
                "isLockedPro": false,
                "commentCount": 73,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "With Harvoni Approved, Here's What's Next For Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "36201",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": []
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2560215-with-harvoni-approved-heres-whats-next-for-gilead-sciences"
            }
        },
        {
            "id": "2557325",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-13T10:23:43-04:00",
                "isLockedPro": false,
                "commentCount": 76,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Updating My Price Target On Gilead Sciences",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "25562",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "142949",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2557325-updating-my-price-target-on-gilead-sciences"
            }
        },
        {
            "id": "2554095",
            "type": "article",
            "attributes": {
                "publishOn": "2014-10-10T15:05:00-04:00",
                "isLockedPro": false,
                "commentCount": 37,
                "gettyImageUrl": null,
                "videoPreviewUrl": null,
                "videoDuration": null,
                "themes": {},
                "title": "Update: FDA Approves Gilead's Harvoni - We Reaffirm Our Bull Case",
                "structuredInsights": null,
                "isPaywalled": false
            },
            "relationships": {
                "author": {
                    "data": {
                        "id": "44981",
                        "type": "author"
                    }
                },
                "sentiments": {
                    "data": [
                        {
                            "id": "142855",
                            "type": "sentiment"
                        }
                    ]
                },
                "primaryTickers": {
                    "data": [
                        {
                            "id": "1089",
                            "type": "tag"
                        }
                    ]
                },
                "secondaryTickers": {
                    "data": []
                },
                "otherTags": {
                    "data": []
                }
            },
            "links": {
                "self": "/article/2554095-update-fda-approves-gileads-harvoni-we-reaffirm-our-bull-case"
            }
        }
    ]
}